Paper Details

  1. Home
  2. Paper Details

Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.

Author: AntinoriAndrea, ArribasJosé R, BlochMark, BosseMatthew, ChuckSusan K, CohenCalvin J, De-OertelShampa, GarnerWill, PiontkowskyDavid, PorterDanielle, RachlisAnita, RiegerArmin, Segal-MaurerSorana, WohlDavid A, van LunzenJan

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study compared the efficacy, safety, tolerability, and patient-reported outcomes of two single-tablet regimens for HIV-1-infected treatment-naive adults: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). After 96 weeks, RPV/FTC/TDF was noninferior to EFV/FTC/TDF in terms of viral suppression but was significantly more efficacious in patients with lower baseline viral loads and higher CD4 cell counts. RPV/FTC/TDF was associated with fewer adverse events, particularly central nervous system issues and rash. It also showed greater improvements in patient-reported symptoms and quality of life.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To compare efficacy, safety, tolerability, and patient-reported outcomes between two single-tablet regimens, rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF), in HIV-1-infected, treatment-naive a...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26684822

データ提供：米国国立医学図書館（NLM）

Rilpivirine vs. Efavirenz: A Duel in the Desert of HIV Treatment

HIV infection presents a complex challenge for healthcare professionals, demanding effective and well-tolerated treatment options. This study compares the efficacy and safety of two single-tablet regimens for HIV-1-infected, treatment-naive adults: rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF). The study utilizes a randomized, open-label, international, noninferiority trial design, offering a robust assessment of these two treatment approaches.

The study’s findings reveal that RPV/FTC/TDF demonstrated noninferior efficacy compared to EFV/FTC/TDF over a 96-week period. Additionally, RPV/FTC/TDF was associated with significantly fewer adverse events, particularly those related to central nervous system issues and rashes, suggesting a more favorable tolerability profile. This is like comparing two caravans traversing a challenging desert landscape, one equipped with more robust and comfortable vehicles and a smoother navigation route, resulting in a more pleasant and efficient journey.

A New Frontier in HIV Treatment: A More Tolerable Approach

The study highlights the potential advantages of RPV/FTC/TDF as a treatment option for HIV-1-infected individuals, offering a potentially more tolerable and effective approach to managing this complex condition.

Living with HIV: A Journey of Care and Empowerment

The research underscores the importance of optimizing HIV treatment regimens to enhance patient tolerability and improve quality of life. It’s a reminder that the journey through the desert of HIV infection is best navigated with a collaborative approach between healthcare professionals and patients, working together to create a path toward well-being and empowerment.

Dr. Camel's Conclusion

This study provides valuable insights into the potential benefits of RPV/FTC/TDF for HIV-1-infected individuals, suggesting a potentially more effective and tolerable treatment option that can enhance patient care and improve the journey through this challenging disease.

Date :
  1. Date Completed 2016-10-06
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26684822

DOI: Digital Object Identifier

00002030-201601140-00011

Related Literature

Article Analysis
・Side Effects of rilpivirine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.